Compare DexCom, Inc. (DXCM) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? DexCom, Inc. trades at $90.23 (market cap $33.79B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.92. The key difference: DexCom, Inc. is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | PDBC | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | — |
52-Week High | $89.53 | $18.91 |
52-Week Low | $54.84 | $12.90 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
PDBC trades at $17.87, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on diversified commodities, avoiding K-1 tax forms, and has seen strong institutional inflows, including a 150.6% position increase by Geneos Wealth Management in Q1 2026 (SEC filing, 2026-07-19). Recent news highlights commodities' role as an inflation hedge, with PDBC returning 37% since March 2024, though momentum has weakened recently (Seeking Alpha, 2026-06-11).
The outlook for PDBC is supported by geopolitical tensions and inflation hedging demand, but risks include commodity price volatility and Middle East conflicts. Wall Street sentiment is mixed, with a recent downgrade to hold due to fading momentum, yet institutional interest remains strong, indicating long-term confidence in commodities exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
